Determining the Societal Value of a Prospective Drug for ME/CFS in Germany

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Jul 18

PMID 39024303

Authors

Afschin Gandjour

Affiliations

Soon will be listed here.

Abstract

Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) imposes a substantial societal and economic burden. The aim of this study is to ascertain the optimal level of public research and development (R&D) investment in Germany for a prospective drug, given the pressing need for effective treatments.

Methods: This study calculates the societal value from a German perspective by integrating health and economic outcomes in the context of public R&D investment for ME/CFS. It considers factors such as direct medical costs, productivity loss, and the effectiveness of a prospective drug.

Results: The anticipated introduction of a prospective drug is estimated to yield a quality-adjusted life year (QALY) gain of approximately 29,000 and a societal value of about €2.6 billion. The optimal R&D investment in Germany is estimated at €676 million, which represents about a quarter of the total investment required to bring a significant drug to market, considering diminishing returns and market constraints. Results were confirmed in the sensitivity analysis.

Conclusions: The study concludes that a coordinated international approach is imperative to address the funding and market size limitations effectively in developing treatments for ME/CFS and to realize the substantial societal and economic benefits.

References

Gandjour A . Underuse of innovative medicines in Germany: A justification for government intervention?. Health Policy. 2018; 122(12):1283-1286. DOI: 10.1016/j.healthpol.2018.08.009. View

Collin S, Crawley E, May M, Sterne J, Hollingworth W . The impact of CFS/ME on employment and productivity in the UK: a cross-sectional study based on the CFS/ME national outcomes database. BMC Health Serv Res. 2011; 11:217. PMC: 3184626. DOI: 10.1186/1472-6963-11-217. View

Hvidberg M, Brinth L, Olesen A, Petersen K, Ehlers L . The Health-Related Quality of Life for Patients with Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS). PLoS One. 2015; 10(7):e0132421. PMC: 4492975. DOI: 10.1371/journal.pone.0132421. View

Valdez A, Hancock E, Adebayo S, Kiernicki D, Proskauer D, Attewell J . Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning. Front Pediatr. 2019; 6:412. PMC: 6331450. DOI: 10.3389/fped.2018.00412. View

Hanly P, Timmons A, Walsh P, Sharp L . Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach. Value Health. 2012; 15(3):429-36. DOI: 10.1016/j.jval.2011.12.012. View

Gandjour A . Long COVID: Costs for the German economy and health care and pension system. BMC Health Serv Res. 2023; 23(1):641. PMC: 10266873. DOI: 10.1186/s12913-023-09601-6. View

Renz-Polster H, Scheibenbogen C . [Post-COVID syndrome with fatigue and exercise intolerance: myalgic encephalomyelitis/chronic fatigue syndrome]. Inn Med (Heidelb). 2022; 63(8):830-839. PMC: 9281337. DOI: 10.1007/s00108-022-01369-x. View

Maksoud R, Magawa C, Eaton-Fitch N, Thapaliya K, Marshall-Gradisnik S . Biomarkers for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review. BMC Med. 2023; 21(1):189. PMC: 10206551. DOI: 10.1186/s12916-023-02893-9. View

Medlinskiene K, Tomlinson J, Marques I, Richardson S, Stirling K, Petty D . Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review. BMC Health Serv Res. 2021; 21(1):1198. PMC: 8570007. DOI: 10.1186/s12913-021-07196-4. View

10.

Joseph P, Pari R, Miller S, Warren A, Stovall M, Squires J . Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine. Chest. 2022; 162(5):1116-1126. DOI: 10.1016/j.chest.2022.04.146. View

11.

Bonilla H, Peluso M, Rodgers K, Aberg J, Patterson T, Tamburro R . Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023; 14:1129459. PMC: 10034329. DOI: 10.3389/fimmu.2023.1129459. View

12.

Zhao T, Cox I, Ahmad H, Campbell J, Hensher M, Palmer A . The economic burden of myalgic encephalomyelitis/chronic fatigue syndrome in Australia. Aust Health Rev. 2023; 47(6):707-715. DOI: 10.1071/AH23106. View

13.

Cleary E, Jackson M, Zhou E, Ledley F . Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019. JAMA Health Forum. 2023; 4(4):e230511. PMC: 10148199. DOI: 10.1001/jamahealthforum.2023.0511. View

14.

Gandjour A . A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany. Appl Health Econ Health Policy. 2023; 21(4):627-635. PMC: 10088581. DOI: 10.1007/s40258-023-00803-x. View

15.

Estevez-Lopez F, Mudie K, Wang-Steverding X, Bakken I, Ivanovs A, Castro-Marrero J . Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology. J Clin Med. 2020; 9(5). PMC: 7290765. DOI: 10.3390/jcm9051557. View

16.

Koopmanschap M, van Ineveld B . Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992; 34(9):1005-10. DOI: 10.1016/0277-9536(92)90131-9. View

17.

Gandjour A, Schussler S, Hammerschmidt T, Dintsios C . Predictors of negotiated prices for new drugs in Germany. Eur J Health Econ. 2020; 21(7):1049-1057. PMC: 7423852. DOI: 10.1007/s10198-020-01201-z. View